Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.54 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.54 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 6/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 4/20 | 0.47 |
| ▸ | MMP13 | P45452 | 4/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | MMP3 | P08254 | 2/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.47 |
| ▸ | SQSTM1 | Q13501 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL810235 | 1.00 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1ALDH1A1POLB | |
| SCHEMBL2240506 | 1.00 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1ALDH1A1POLB | |
| SCHEMBL2240510 | 1.00 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1ALDH1A1POLB | |
| SCHEMBL7093075 | 1.00 | SLC1A3 (0.54) | SLC1A3SLC1A2SLC1A1ALDH1A1POLB | |
| SCHEMBL7091907 | 0.99 | SLC1A3 (0.53) | SLC1A3SLC1A2SLC1A1ALDH1A1POLB | |
| P-Cymene SCHEMBL6740530 | 0.89 | CNR1 (0.51) | SLC1A3SLC1A2SLC1A1ALDH1A1POLB | |
| P-Cymene SCHEMBL7513368 | 0.89 | CNR1 (0.51) | SLC1A3SLC1A2SLC1A1ALDH1A1POLB | |
| SCHEMBL13566636 | 0.88 | CNR1 (0.57) | SLC1A3SLC1A2SLC1A1ALDH1A1CNR1 | |
| SCHEMBL12674763 | 0.88 | CNR1 (0.57) | SLC1A3SLC1A2SLC1A1ALDH1A1CNR1 | |
| SCHEMBL10054196 | 0.88 | CNR1 (0.57) | SLC1A3SLC1A2SLC1A1ALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2868659-B1 | Method for producing optically active naphthalene compound | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-04 | — | — | EP | claimed |
| US-9181217-B2 | Method for producing optically active naphthalene compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-11-10 | — | — | US | claimed |
| US-20150152082-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE NAPHTHALENE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-06-04 | — | — | US | claimed |
| EP-2868659-A1 | Method for producing optically active naphthalene compound | Mitsubishi Tanabe Pharma Corporation (JP) | 2015-05-06 | — | — | EP | claimed |
| EP-2749558-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE NAPHTHALENE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2014-07-02 | — | — | EP | claimed |
| EP-0915076-B1 | Process for the preparation of trans-(R,R)-actinol | HOFFMANN LA ROCHE (CH) | 2002-01-16 | — | — | EP | claimed |
| EP-0920809-B1 | Molded filamentary mesh-structured chocolate and method of producing the same | LOTTE CO LTD (JP) | 2002-01-09 | — | — | EP | claimed |
| US-6187961-B1 | HYDROGENATING (R)-LEVODIONE IN PRESENCE OF HYDROGEN DONAR AND A SOLVENT OR IN PRESENCE OF HYDROGEN DONOR WHICH SIMULTANEOUSLY USED AS THE SOLVENT, AND AN AMINO-AMIDE-RUTHENIUM COMPLEX | ROCHE VITAMINS INC. | 2001-02-13 | — | — | US | claimed |
| US-6099886-A | Molded filamentary mesh-structured chocolate and method of producing the same | LOTTE CO., LTD. (JP) | 2000-08-08 | — | — | US | claimed |
| EP-0920809-A2 | Molded filamentary mesh-structured chocolate and method of producing the same | LOTTE CO., LTD (JP) | 1999-06-09 | — | — | EP | claimed |
| EP-0915076-A1 | Process for the preparation of trans-(R,R)-actinol | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | claimed |
| CN-114230713-B | Method for reducing surface fusion and surface adhesion of high internal phase emulsion in polymerization process | 苏州星日化学有限公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-114835843-A | Method for continuously preparing stable and uniform high internal phase emulsion | 苏州星日化学有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114395165-A | Recycling method for producing high internal phase emulsion foam electrolyte-containing wastewater by continuous method | 苏州星日化学有限公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-2868659-B1 | Method for producing optically active naphthalene compound | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-04 | — | — | EP | disclosed |
| US-6300509-B1 | CATALYST FOR DIASTEREOSELECTIVE TRANSFER HYDROGENATION OF (R)-LEVODIONE TO TRANS-(R,R)-ACTINOL IN PRESENCE OF HYDROGEN DONOR, WHICH SIMULTANEOUSLY CAN BE USED AS SOLVENT | ROCHE VITAMINS INC. | 2001-10-09 | — | — | US | disclosed |
| US-6187961-B1 | HYDROGENATING (R)-LEVODIONE IN PRESENCE OF HYDROGEN DONAR AND A SOLVENT OR IN PRESENCE OF HYDROGEN DONOR WHICH SIMULTANEOUSLY USED AS THE SOLVENT, AND AN AMINO-AMIDE-RUTHENIUM COMPLEX | ROCHE VITAMINS INC. | 2001-02-13 | — | — | US | disclosed |
| US-6099886-A | Molded filamentary mesh-structured chocolate and method of producing the same | LOTTE CO., LTD. (JP) | 2000-08-08 | — | — | US | disclosed |
| EP-0920809-A2 | Molded filamentary mesh-structured chocolate and method of producing the same | LOTTE CO., LTD (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0915076-A1 | Process for the preparation of trans-(R,R)-actinol | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152082-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE NAPHTHALENE COMPOUND | HRH1, HRH4, RB1 | SLC1A3 4437/4885SLC1A2 4280/4885SLC1A1 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.